Breaking Through Inertia: How to Initiate and Maintain Insulin Therapy in Patients with Type 2 Diabetes

This interactive infographic covers a variety of topics surrounding the role of insulin therapy in type 2 diabetes (T2D) management, including practical pearls for initiation and maintenance of insulin therapy, how insulin therapy fits in with other T2D treatment options, and emerging insulin options. The information is presented in an interactive format, which contains a mix of high-impact visuals, infographics, expert faculty videos, as well as resources and suggested readings, all organized into different segments to facilitate learning.

Target Audience

The educational design of this activity addresses the needs of US-based healthcare professionals, including primary care physicians and family physicians.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify patients with T2DM who are likely to benefit from insulin therapy based on current guidelines, evidence, and treatment goals
  • Review the efficacy and safety of different insulin options for T2DM
  • Summarize the rationale, efficacy and safety of emerging longer-acting basal insulins for T2DM management
  • Develop individualized treatment regimens for patients with T2DM that include the initiation and maintenance of insulin therapy based on current guidelines and patient-specific considerations


Additional Information

PDF icon PDF Slides2.33 MB
Course summary
Available credit: 
  • 1.50 AAFP
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 Participation
Course opens: 
Course expires: 

Davida F. Kruger, MSN, APN-BC, BC-ADMD
Certified Nurse Practitioner
Henry Ford Health System
Division of Endocrinology, Diabetes,  
Bone and Mineral Disease
Detroit, MI

Jay H. Shubrook, DO, FAAFP, FACOFP
Professor, and Interim Chair
Department of Clinical Sciences and Community Health 
Touro University California  
College of Osteopathic Medicine
Vallejo, CA

1.5 hours


Supported by an educational grant from Novo Nordisk

A picture containing text, clipart    Description automatically generated

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


PACE designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The AAFP has reviewed Breaking Through Inertia: How To Initiate and Maintain Insulin Therapy in Patients with Type 2 Diabetes and deemed it acceptable for up to 1.50 Enduring Materials, Self-Study AAFP Prescribed credit(s). Term of Approval is from 04/08/2024 to 04/08/2025. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)TM toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.


There are no registration fees for this activity. Participation in this self-study activity should be completed in approximately 1.5 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from April 8, 2024 through April 8, 2025.

  1. Review the objectives and disclosures
  2. Study the educational content
  3. Successfully complete activity post-test(s)
  4. Complete the activity evaluation

You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at For additional information about the accreditation of this activity, please visit


PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Ms. Kruger, faculty for this educational activity, discloses the following:

  • Grant Research: Novo Nordisk, Eli Lilly, Dexcom, Abbott
  • Speaker Fees: Novo Nordisk, Janssen, Eli Lilly, BI, Sanofi, Dexcom, Abbott, Intarsia, AZ
  • Stockholder: Dexcom

Dr. Shubrook, faculty for this educational activity, discloses the following:

  • Consultant: Abbott, Bayer, Novo Nordisk
  • Advisor: Astra Zeneca, Eli Lilly, Nevro


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Available Credit

  • 1.50 AAFP
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.